Core Insights - Okogen Inc. has acquired the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc., enhancing its lead ophthalmic program and laying the groundwork for expansion into additional antiviral indications [1][7]. Company Overview - Okogen Inc. is a biotechnology company focused on developing antiviral therapeutics targeting ocular infections, respiratory viruses, and emerging infectious diseases. Its lead candidate, OKG-0303, is aimed at treating acute infectious conjunctivitis [4]. Ranpirnase Details - Ranpirnase is a ribonuclease enzyme that disrupts viral replication by degrading intracellular RNA, creating a bottleneck in viral protein production. This mechanism offers a differentiated approach to antiviral development, potentially reducing resistance seen with traditional antivirals. Ranpirnase has been evaluated in clinical trials with over 1,000 patients, providing substantial safety and translational data for further development [5]. Development Strategy - The company is prioritizing the rapid advancement of its ranpirnase program, OKG-0303, which addresses a fragmented treatment landscape for acute infectious conjunctivitis. Okogen is also exploring ranpirnase as a potential antiviral countermeasure against high-consequence pathogens like Marburg and Sudan viruses, while conducting parallel research on respiratory viruses such as influenza and RSV [7].